The COVID‑19 outbreak has been a scourge for cancer patients. The absence of knowledge and ignorance in addressing cancer patients throughout this epidemic has deteriorated their illnesses. Gathering information about patients undergoing immunotherapy during the COVID-19 pandemic was the study's goal. The information gathered covered the diagnosis, some research, and the effects of the immunotherapy medications as well as their adverse effects. To examine the actual situation, we looked at 13 patients who received immunotherapy during the COVID-19 epidemic and attempted to determine whether they experienced any severe side effects. This pilot project would serve as a foundation for larger research projects in the future. Immunotherapy medications including nivolumab, pembrolizumab, and atezolizumab were administered to our patients regularly during the COVID outbreak, which lasted from March 20 to June 20. Six individuals received nivolumab, six received pembrolizumab, and one received atezolizumab. Four patients were getting immunotherapy for lung cancer, three for head and neck cancer, two for recurrent lymphoma, and one each for hepatocellular carcinoma, renal cell cancer, malignant melanoma, and soft-tissue cancer among the 13 patients who continued to receive immunotherapy during the COVID pandemic. After taking pembrolizumab, one of the patients on atezolizumab improved. The majority of our patients remained in stable illness or partial remission, and there was no Grade 3 or 4 toxicity to these medications. One patient passed away shortly after starting a nivolumab cycle. For both the patients and the treating oncologist, the COVID-19 infection has presented an unexpected dilemma. It is extremely challenging to treat cancer patients when there is no prior evidence and the treatment is believed to be harmful. In this modest attempt, we hope to raise awareness that immunotherapy may continue throughout the COVID-19 epidemic as long as all necessary safeguards are taken.
